Nektar Therapeutics (NKTR) shares were up over 16% in recent Monday trading after the company said it agreed to sell its Huntsville, Alabama, manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million.
The consideration comprises $70 million in cash and a $20 million equity position in a newly created Ampersand portfolio company that will house the Huntsville-based facility, according to the statement.
In addition, Nektar said it will sign manufacturing supply agreements with the new Ampersand company for its PEG reagent needs.
The deal is expected to close by Dec. 2 and Nektar said it will retain all rights to current and future royalty streams and milestones related to its existing PEGylated product license deals.
Nektar Chief Executive Howard Robin said the sale streamlines the company's operations and extends its cash runway into Q4 2026.
Price: 1.43, Change: +0.20, Percent Change: +16.26
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。